Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

July 06, 2020   |   July 2020 Bond Updates
SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate...

View more at: https://www.prnewswire.com:443/news-releases/ascentage-pharma-announces-clinical-trial-collaboration-agreement-with-msd-to-evaluate-apg-115-in-combination-with-keytruda-pembrolizumab-in-advanced-solid-tumors-301088223.html
 
Related News
Home| About us | Contact us http://www.bondupdatesdailynews.com/